Azurity Pharmaceuticals Solidifies Leadership with Covis Pharma Acquisition

In a significant move in the pharmaceutical industry, Azurity Pharmaceuticals has announced the successful completion of its acquisition of Covis Pharma. This acquisition marks a strategic effort to enhance Azurity's leadership in branded pharmaceuticals by leveraging Covis Pharma’s robust portfolio, which includes a wide range of complex dosage forms and therapeutic areas. Covis, now wholly owned by Azurity, will help expand Azurity's global footprint to over 50 countries and increase its workforce to more than 800 employees across North America, Europe, and Asia. This move is intended to strengthen Azurity's capability to deliver important medications to underserved patients globally. The strategic advantages of this acquisition include expanded therapeutic portfolios, increased global presence, accelerated innovation opportunities, and positioning Azurity as a partner of choice in the biopharmaceutical sector. QHP Capital, as the majority owner of Azurity, expressed its continued support and belief in Azurity's growth trajectory and strategic vision. Financial advisory for the acquisition was provided by Goldman Sachs, with legal counsel from Eversheds Sutherland and White & Case for Azurity, while Covis was advised by Guggenheim Securities with Reed Smith and A&O Shearman as legal advisors.